Public Employees Benefits Program board approves phased‑in health‑insurance rate changes after heated public comment

The Public Employees Benefits Program Board voted March 19 to adopt a phased package of premium adjustments intended to address budget shortfalls and rising health‑care costs while limiting the immediate shock to employees.

The board approved a compromise that applies a three‑year phase‑in (Seagull scenario 1C) to the consumer‑driven health plan (CDHP) and the low‑deductible preferred option (LDPO), and a shorter, two‑year phase‑in (1B) for the EPO/HMO plan. The motion passed on a 4–3 vote after earlier attempts to adopt a different option failed.

The vote followed a lengthy budget presentation and an actuary briefing that identified drivers of rising costs — from specialty drugs and cancer therapies to a steep pharmacy trend tied partly to GLP‑1 medicines — and after a day of public comment by dozens of state employees, retiree advocates and union representatives who called the proposed increases unbearable.

Why this matters: The board must balance a statutory responsibility to keep the program solvent with the goal of preserving affordable benefits for roughly 17,000 participants. Seagull, the board’s actuary, recommended resetting stand‑alone rates to remove long‑running cross‑subsidies that have left some plans underpriced; the firm projected a blended plan‑year 2027 trend of about 7.3% (roughly 6% medical and 11% pharmacy).

What the board approved: Under the adopted package the CDHP and LDPO will see their standalone rates phased in over three years; the EPO/HMO will move to rates closer to stand‑alone pricing on a faster, two‑year schedule. The board also authorized limited transfers from legacy subsidy accounts (Aegis/Reggie) to reduce the immediate member increase — staff estimated about $9.4 million of relief from those accounts — and set a policy that will cap retiree years‑of‑service discounts so no retiree premium for the same single enrollment will fall below what an active employee pays; implementation of that retiree cap was set for plan year 2028 to allow operational implementation.

Board debate and public reaction: Dozens of callers said the proposed changes would be catastrophic for lower‑paid staff, urging a delay or a three‑year phase in that would be gentler on households. “This is essentially a $13,000 pay cut for anyone on that plan,” said Kevin Sauls, a state employee who testified that his family’s EPO premium could rise from roughly $700–$800 to about $1,800 per month under some options. Retiree advocates pressed the board not to double‑count retirees’ protections while unions and employee groups asked the board to seek more state support and to postpone the decision until legislative budget work and an audit were complete.

Actuarial context: Deborah Donaldson of Seagull told the board that national and PB‑specific pharmacy trends are unusually high, driven by specialty drugs and an expanding role for GLP‑1 medicines used for diabetes and weight loss. She cautioned that re‑pricing plans to stand alone without carefully modeled migration assumptions can cause members to shift plans in ways that change the risk mix and downstream costs.

Procedural details and next steps: The board directed staff to continue monthly reconciliation of corrected payroll and subsidy entries, and to pursue cost‑containment and vendor negotiations (including pharmacy rebate terms) as part of ongoing work. Staff indicated corrected subsidy entries will appear in the quarter‑three CFO report and that audit work on prior fiscal years will proceed in summer 2026. The board’s adopted rate schedule will be used for plan‑year 2027 budgeting and open‑enrollment notices; staff said they would publish refined materials and member notices consistent with legal timing requirements for enrollment.

Who said what: Supporters of delaying or scaling back increases included representatives of the Nevada Faculty Alliance and the Retired Public Employees of Nevada; Terry Leair of RPN told the board retirees “earned the benefits they receive today” and urged protection of existing coverage. Seagull actuaries Deborah Donaldson and Amy McClendon emphasized the need to reflect corrected revenue projections and to address rising specialty drug spend. Monica (CFO) told the board she had discovered $18.44 million in subsidy revenue that had not been moved to the operational budget and would be reflected in Q3 reports.

What the board did not do: The board did not adopt the option that would have implemented full stand‑alone rates immediately; an initial motion for one such option failed 3–4. The final compromise seeks to reduce immediate harm while beginning to close long‑running cross‑subsidies.

What to watch: Staff said they will continue to refine revenue and payroll reconciliations, negotiate pharmacy contracts and rebates, and return with operational details — including exact dollar impacts on each enrollment tier — as materials are finalized for open enrollment. The actuarial assumptions and the board’s migration assumptions will be revisited as claims and enrollment experience for plan year 2026 becomes complete.